跳至主要内容
临床试验/NL-OMON50064
NL-OMON50064招募中不适用

A Randomised Feasibility n-of-1 Trial of Weekly-Interval Red Cell Transfusion in myelodysplastic syndromes; Red blood cell transfusion schedule in myelodysplastic syndromes (REDDS): study 2 - REDDS2

Transfusion Research Unit, Monash University, Australia0 个研究点目标入组 3 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Patients aged >=18 years with WHO-defined MDS or mixed
  • myeloproliferative/myelodysplastic neoplasm overlap syndromes (MPN/MDS)
  • - Transfusion dependent: at least two transfusion episodes and at least four
  • units of RBCs in total during the 16 weeks prior to study entry
  • - Continuing RBC transfusion requirement expected for at least 6 months

排除标准

  • - Currently receiving RBC transfusion at an interval of <=7 days
  • - Unable to tolerate a weekly transfusion schedule, as determined by the
  • treating clinician
  • - Patients on erythropoietic-stimulating agent (ESA) or disease-modifying
  • agents for their MDS (such as lenalidomide, azacitidine, hydroxycarbamide,
  • experimental agents)

研究者

发起方
Transfusion Research Unit, Monash University, Australia

相似试验